Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruce Ross

Orthopaedic Surgery Mineola, NY Medical Doctor

NPI 1295708600 CMS profile 148766

161 Willis Ave, Mineola, NY 11501

Open in the dashboard

General payments

$982

53 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bruce Ross of Mineola, NY is reported in the CMS Open Payments database as having received $982 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 29th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43 2
2024 General $212 13
2023 General $220 9
2022 General $37 2
2021 General $203 11
2020 General $95 5
2019 General $172 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Ross
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Bruce Ross were reported at $43. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Bruce Ross Orthopaedic Surgery median Middle half National median
2019 $172 $644 $140–$2,844 $163
2020 $95 $312 $75–$1,860 $114
2021 $203 $520 $117–$2,495 $132
2022 $37 $598 $128–$2,731 $149
2023 $220 $461 $128–$2,264 $160
2024 $212 $497 $134–$2,475 $164
2025 $43 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bioventus LLC $524 28 payments
  2. DePuy Synthes Sales Inc. $186 9 payments
  3. Horizon Therapeutics plc $161 10 payments
  4. Ferring Pharmaceuticals Inc. $40 2 payments
  5. Zyla Life Sciences $33 2 payments
  6. Zimmer Biomet Holdings, Inc. $22 1 payment
  7. Sanofi-Aventis U.S. LLC $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $982 53 payments
Products named General payments · program years 2019–2025
  1. Durolane Orthopedics/Orthopedic Surgery $164 6 payments
  2. MONOVISC $148 7 payments
  3. EXOGEN ULTRASOUND BONE HEALING SYSTEM Devices $107 7 payments
  4. Exogen Ultrasound Bone Healing System Not Applicable $107 6 payments
  5. ORTHOVISC $91 4 payments
  6. PENNSAID $69 4 payments
  7. VIMOVO Vimovo $57 4 payments
  8. VIMOVO Vimovo $57 4 payments
  9. Durolane Orthopedics/Orthopedic Surgery $53 3 payments
  10. EUFLEXXA $40 2 payments
  11. Other $339 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

173

Median for Orthopedic Surgery: 203

Drug cost

$640

Median for Orthopedic Surgery: $1,433

Branded share of claims

11.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 35 $233
Meloxicam Generic 74 $206
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 20 $106
Duloxetine Hcl Generic 12 $51
Tramadol Hcl Generic 32 $44

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$196,415

Of which drugs: $5,913

Medicare patients

326

Average age 76

Services billed

4,631

194 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Ischemic heart disease 33%
Diabetes 28%
Atrial fibrillation 17%
Cancer 15%
Chronic kidney disease 14%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 69 83 $334
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 18 82 $113
Injection, methylprednisolone acetate, 1 mg J1010 Office 169 272 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record